Geranylgeranylacetone selectively binds to the HSP70 of Helicobacter pylori and alters its coccoid morphology

Ewa Grave, Shin Ichi Yokota, Soh Yamamoto, Arisa Tamura, Takako Ohtaki-Mizoguchi, Kenji Yokota, Keiji Oguma, Kazuhiko Fujiwara, Nobuaki Ogawa, Tomoya Okamoto, Michiro Otaka, Hideaki Itoh

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Geranylgeranylacetone (GGA) is used to treat patients suffering from peptic ulcers and gastritis. We examined the effect of GGA on Helicobacter pylori, which is a causative factor of gastrointestinal diseases. Previously, we have reported that GGA binds specifically to the molecular chaperone HSP70. In this paper, we report that GGA bounds to H. pylori HSP70 (product of the DnaK gene) with 26-times higher affinity than to human HSP70, and induced large conformational changes as observed from surface plasmon resonance and circular dichroism. Binding of GGA suppressed the activity of the H. pylori chaperone. GGA also altered several characteristics of H. pylori cells. GGA-treated cells elicited enhanced interleukin-8 production by gastric cancer cell lines and potentiated susceptibility to complement as compared to untreated cells. GGA also caused morphological alterations in H. pylori as reflected in fewer coccoid-like cells, suggesting that GGA converts H. pylori to an actively dividing, spiral state (vegetative form) from a non-growing, coccoid state. This morphological conversion by GGA resulted in accelerated growth of H. pylori. These results suggest a model in which GGA sensitizes H. pylori to antibiotic treatment by converting the cells to an actively growing state.

Original languageEnglish
Article number13738
JournalScientific Reports
Volume5
DOIs
Publication statusPublished - Sep 8 2015

Fingerprint

geranylgeranylacetone
Helicobacter pylori
Persistent Vegetative State

ASJC Scopus subject areas

  • General

Cite this

Geranylgeranylacetone selectively binds to the HSP70 of Helicobacter pylori and alters its coccoid morphology. / Grave, Ewa; Yokota, Shin Ichi; Yamamoto, Soh; Tamura, Arisa; Ohtaki-Mizoguchi, Takako; Yokota, Kenji; Oguma, Keiji; Fujiwara, Kazuhiko; Ogawa, Nobuaki; Okamoto, Tomoya; Otaka, Michiro; Itoh, Hideaki.

In: Scientific Reports, Vol. 5, 13738, 08.09.2015.

Research output: Contribution to journalArticle

Grave, E, Yokota, SI, Yamamoto, S, Tamura, A, Ohtaki-Mizoguchi, T, Yokota, K, Oguma, K, Fujiwara, K, Ogawa, N, Okamoto, T, Otaka, M & Itoh, H 2015, 'Geranylgeranylacetone selectively binds to the HSP70 of Helicobacter pylori and alters its coccoid morphology', Scientific Reports, vol. 5, 13738. https://doi.org/10.1038/srep13738
Grave, Ewa ; Yokota, Shin Ichi ; Yamamoto, Soh ; Tamura, Arisa ; Ohtaki-Mizoguchi, Takako ; Yokota, Kenji ; Oguma, Keiji ; Fujiwara, Kazuhiko ; Ogawa, Nobuaki ; Okamoto, Tomoya ; Otaka, Michiro ; Itoh, Hideaki. / Geranylgeranylacetone selectively binds to the HSP70 of Helicobacter pylori and alters its coccoid morphology. In: Scientific Reports. 2015 ; Vol. 5.
@article{ba12998c6022496cb52a115d0a0fd1d2,
title = "Geranylgeranylacetone selectively binds to the HSP70 of Helicobacter pylori and alters its coccoid morphology",
abstract = "Geranylgeranylacetone (GGA) is used to treat patients suffering from peptic ulcers and gastritis. We examined the effect of GGA on Helicobacter pylori, which is a causative factor of gastrointestinal diseases. Previously, we have reported that GGA binds specifically to the molecular chaperone HSP70. In this paper, we report that GGA bounds to H. pylori HSP70 (product of the DnaK gene) with 26-times higher affinity than to human HSP70, and induced large conformational changes as observed from surface plasmon resonance and circular dichroism. Binding of GGA suppressed the activity of the H. pylori chaperone. GGA also altered several characteristics of H. pylori cells. GGA-treated cells elicited enhanced interleukin-8 production by gastric cancer cell lines and potentiated susceptibility to complement as compared to untreated cells. GGA also caused morphological alterations in H. pylori as reflected in fewer coccoid-like cells, suggesting that GGA converts H. pylori to an actively dividing, spiral state (vegetative form) from a non-growing, coccoid state. This morphological conversion by GGA resulted in accelerated growth of H. pylori. These results suggest a model in which GGA sensitizes H. pylori to antibiotic treatment by converting the cells to an actively growing state.",
author = "Ewa Grave and Yokota, {Shin Ichi} and Soh Yamamoto and Arisa Tamura and Takako Ohtaki-Mizoguchi and Kenji Yokota and Keiji Oguma and Kazuhiko Fujiwara and Nobuaki Ogawa and Tomoya Okamoto and Michiro Otaka and Hideaki Itoh",
year = "2015",
month = "9",
day = "8",
doi = "10.1038/srep13738",
language = "English",
volume = "5",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Geranylgeranylacetone selectively binds to the HSP70 of Helicobacter pylori and alters its coccoid morphology

AU - Grave, Ewa

AU - Yokota, Shin Ichi

AU - Yamamoto, Soh

AU - Tamura, Arisa

AU - Ohtaki-Mizoguchi, Takako

AU - Yokota, Kenji

AU - Oguma, Keiji

AU - Fujiwara, Kazuhiko

AU - Ogawa, Nobuaki

AU - Okamoto, Tomoya

AU - Otaka, Michiro

AU - Itoh, Hideaki

PY - 2015/9/8

Y1 - 2015/9/8

N2 - Geranylgeranylacetone (GGA) is used to treat patients suffering from peptic ulcers and gastritis. We examined the effect of GGA on Helicobacter pylori, which is a causative factor of gastrointestinal diseases. Previously, we have reported that GGA binds specifically to the molecular chaperone HSP70. In this paper, we report that GGA bounds to H. pylori HSP70 (product of the DnaK gene) with 26-times higher affinity than to human HSP70, and induced large conformational changes as observed from surface plasmon resonance and circular dichroism. Binding of GGA suppressed the activity of the H. pylori chaperone. GGA also altered several characteristics of H. pylori cells. GGA-treated cells elicited enhanced interleukin-8 production by gastric cancer cell lines and potentiated susceptibility to complement as compared to untreated cells. GGA also caused morphological alterations in H. pylori as reflected in fewer coccoid-like cells, suggesting that GGA converts H. pylori to an actively dividing, spiral state (vegetative form) from a non-growing, coccoid state. This morphological conversion by GGA resulted in accelerated growth of H. pylori. These results suggest a model in which GGA sensitizes H. pylori to antibiotic treatment by converting the cells to an actively growing state.

AB - Geranylgeranylacetone (GGA) is used to treat patients suffering from peptic ulcers and gastritis. We examined the effect of GGA on Helicobacter pylori, which is a causative factor of gastrointestinal diseases. Previously, we have reported that GGA binds specifically to the molecular chaperone HSP70. In this paper, we report that GGA bounds to H. pylori HSP70 (product of the DnaK gene) with 26-times higher affinity than to human HSP70, and induced large conformational changes as observed from surface plasmon resonance and circular dichroism. Binding of GGA suppressed the activity of the H. pylori chaperone. GGA also altered several characteristics of H. pylori cells. GGA-treated cells elicited enhanced interleukin-8 production by gastric cancer cell lines and potentiated susceptibility to complement as compared to untreated cells. GGA also caused morphological alterations in H. pylori as reflected in fewer coccoid-like cells, suggesting that GGA converts H. pylori to an actively dividing, spiral state (vegetative form) from a non-growing, coccoid state. This morphological conversion by GGA resulted in accelerated growth of H. pylori. These results suggest a model in which GGA sensitizes H. pylori to antibiotic treatment by converting the cells to an actively growing state.

UR - http://www.scopus.com/inward/record.url?scp=84941096182&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941096182&partnerID=8YFLogxK

U2 - 10.1038/srep13738

DO - 10.1038/srep13738

M3 - Article

VL - 5

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 13738

ER -